<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545151</url>
  </required_header>
  <id_info>
    <org_study_id>Ver-A-T1D</org_study_id>
    <secondary_id>2020-000435-45</secondary_id>
    <nct_id>NCT04545151</nct_id>
  </id_info>
  <brief_title>Verapamil SR in Adults With Type 1 Diabetes</brief_title>
  <acronym>Ver-A-T1D</acronym>
  <official_title>A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been set up within the framework of the INNODIA network. INNODIA is a global&#xD;
      partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise&#xD;
      and 2 patient organizations, bringing their knowledge and experience together with one common&#xD;
      goal: &quot;To fight type 1 diabetes&quot;. (www.innodia.eu) The overall aim of INNODIA is to advance&#xD;
      in a decisive way how to predict, stage, evaluate and prevent the onset and progression of&#xD;
      type 1 diabetes (T1D).&#xD;
&#xD;
      For this, INNODIA has established a comprehensive and interdisciplinary network of clinical&#xD;
      and basic scientists, who are leading experts in the field of T1D research in Europe and UK&#xD;
      (United Kingdom), with complementary expertise from the areas of immunology, Beta-cell&#xD;
      biology, biomarker research and T1D therapy, joining forces in a coordinated fashion with&#xD;
      industry partners and two foundations, as well as with all major stakeholders in the process,&#xD;
      including regulatory bodies and patients with T1D and their families.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, randomized, double-blind, placebo-controlled study in volunteers&#xD;
      with newly diagnosed diabetes mellitus type 1 (within 6 weeks after diagnosis).&#xD;
&#xD;
      The purpose of the clinical trial is to confirm the effect of 360mg Verapamil sustained&#xD;
      release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to&#xD;
      360 mg) on the preservation of beta-cell function measured as stimulated C-peptide after 12&#xD;
      months compared to placebo.&#xD;
&#xD;
      The study has a cross-over design and a duration of approximately 24 months, consisting of 3&#xD;
      telephone visits and 7 visits at the trial site. The duration of the treatment phase with&#xD;
      verapamil is 12 months, and an additional (optional) follow-up visit will be carried out 12&#xD;
      months after completion of the study. The study procedures are identical in all 20 clinical&#xD;
      centres across Europe and the UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Trial participants and research teams will be blinded to the treatment group for the duration of the trial. The double blinding will be achieved by providing verapamil SR identical placebo tablets.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the stimulated C-peptide response curve</measure>
    <time_frame>At 12 months</time_frame>
    <description>The primary objective is to determine the changes in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) at baseline and after 12 months for 360mg Verapamil SR administered orally once daily versus placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the stimulated C-peptide response curve</measure>
    <time_frame>At 3, 6, 9 and 24 months</time_frame>
    <description>The area under the stimulated C-peptide response curve over the first two hours of a mixed meal tolerance test (MMTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proinsulin and preproinsulin secretion</measure>
    <time_frame>At baseline and 3, 6, 9 and 12 months</time_frame>
    <description>Proinsulin and preproinsulin secretion during the first two hours of a mixed meal tolerance test (MMTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting C-peptide</measure>
    <time_frame>At 12 months</time_frame>
    <description>To determine the effects of 360mg Verapamil SR administered orally once daily on fasting C-peptide and Dried Blood Spot (DBS) C-peptide measurements over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBS C-peptide</measure>
    <time_frame>At baseline, week 4, week 8, and 3, 6, and 9 months</time_frame>
    <description>The DBS (Dried blood spot) C-peptide measurements at all observation times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline, 12 and 24 months</time_frame>
    <description>To determine the effects of 360mg Verapamil SR administered orally once daily on HbA1c daily total insulin dose and continous glucose monitoring (CGM) time in range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoglycaemic episodes</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Number of treatment emergent severe hypoglycaemic episodes. Severe hypoglycaemia denotes severe cognitive impairment requiring external assistance for recovery according to the American Diabetes Association (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DKA</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Number of treatment emergent episodes of diabetic ketoacidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin requirements</measure>
    <time_frame>Baseline, 12 and 24 months</time_frame>
    <description>Change in insulin requirements, baseline to 12 months as the daily total dose (three days average) in units per kg body weight (BW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T1D associated autoantibodies</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in T1D associated autoantibodies (GADA, IAA, IA-2A and ZnT8A) from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continous glucose monitoring (CGM)</measure>
    <time_frame>At Baseline and every 2 weeks prior to each visit (week 4, week 8, and 3, 6, and 9 months)</time_frame>
    <description>Continous glucose monitoring (CGM) time in range (70-140 mg/dL, 3.9-7.8 mmol/L) and (70-180 mg/dL, 3.9-10.0 mmol/L), time above range (&gt;180 mg/dL, &gt;10.0 mmol/L), time below range (&lt;70 mg/dL, &lt; 3.9 mmol/L)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life: DTSQs questionnaire</measure>
    <time_frame>At week 4 , month 6 and month 12.</time_frame>
    <description>Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):&#xD;
the Diabetes Treatment Satisfaction Questionnaire - DTSQs</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life: DTSQc questionnaire</measure>
    <time_frame>At month 12</time_frame>
    <description>Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):&#xD;
the Diabetes Treatment Satisfaction Questionnaire - DTSQc</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life: ADDQoL questionnaire</measure>
    <time_frame>At month 6 and at month 12</time_frame>
    <description>Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):&#xD;
Â· the Audit of Diabetes Dependent Quality of Life - ADDQoL</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life: HypoFear questionnaire</measure>
    <time_frame>At week 4 , at month 6 and at month 12</time_frame>
    <description>Patients' quality of life will be assessed by participant-reported outcome measures (PROMS): the Hypoglycaemia Fear Survey - HFS</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Verapamil SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomised into the verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants will be randomised into the Placebo arm and receive instructions on frequency of administration (daily intake).&#xD;
40 participants on the control arm are expected to complete the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil SR</intervention_name>
    <description>Study drug will be provided in blisters and packaged and labelled. Each package will be labeled as required per country requirement. Labels will be blinded.&#xD;
Drug adminstration:&#xD;
from Day 0 to Week 4: 120 mg once daily&#xD;
from Week 4 to Week 8: 240 mg once daily&#xD;
from Week 8 to Month 12: 360 mg once daily</description>
    <arm_group_label>Verapamil SR</arm_group_label>
    <other_name>Isoptin retard 120 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be provided in blisters and packaged and labelled. Each package will be labeled as required per country requirement. Labels will be blinded.&#xD;
Drug adminstration:&#xD;
from Day 0 to Week 4: 120 mg once daily&#xD;
from Week 4 to Week 8: 240 mg once daily&#xD;
from Week 8 to Month 12: 360 mg once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching Placebo for Verapamil SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
          -  Age â¥18 and &lt;45 years at consent&#xD;
&#xD;
          -  Must have a diagnosis of T1D of within 6 weeks duration at screening (from date of the&#xD;
             first insulin injection)&#xD;
&#xD;
          -  Must have at least one or more diabetes-related autoantibodies present at screening&#xD;
&#xD;
          -  Must have random C-peptide levels â¥100 pmol/L measured at screening&#xD;
&#xD;
          -  Be willing to comply with intensive diabetes management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be immunodeficient or have clinically significant chronic lymphopenia: Leukopenia (&lt;&#xD;
             3,000 leukocytes /ÂµL), neutropenia (&lt;1,500 neutrophils/ÂµL), lymphopenia (&lt;800&#xD;
             lymphocytes/ÂµL), or thrombocytopenia (&lt;100,000 platelets/ÂµL)&#xD;
&#xD;
          -  Have active signs or symptoms of acute infection at the time of screening&#xD;
&#xD;
          -  Be currently pregnant or lactating, or anticipate getting pregnant during the 12&#xD;
             months study period&#xD;
&#xD;
          -  Require use of immunosuppressive agents including chronic use of systemic steroids&#xD;
&#xD;
          -  Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or&#xD;
             Hepatitis C infection&#xD;
&#xD;
          -  Have any complicating medical issues or abnormal clinical laboratory results that may&#xD;
             interfere with study conduct, or cause increased risk to include pre-existing cardiac&#xD;
             disease, chronic obstructive pulmonary disease (COPD), sickle cell disease,&#xD;
             neurological, or blood count abnormalities as judged by the investigator&#xD;
&#xD;
          -  Have a history of malignancies other than skin&#xD;
&#xD;
          -  Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine&#xD;
             transaminase (ALT) greater than 3 times the upper limits of normal&#xD;
&#xD;
          -  Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control&#xD;
             within prior 7 days of screening&#xD;
&#xD;
          -  Use of any other investigational drug in the previous 30 days and/or intent on using&#xD;
             any investigational drug for the duration of the trial&#xD;
&#xD;
          -  Current use of verapamil or other calcium channel blockers&#xD;
&#xD;
          -  Known hypersensitivity to verapamil or to any of the excipients, use of beta-blockers&#xD;
             in patients with poor ventricular function, concomitant ingestion of grapefruit juice,&#xD;
             combination with ivabradine&#xD;
&#xD;
          -  Hypotension (of less than 90mmHg systolic), sick sinus syndrome (except in patients&#xD;
             with a functioning artificial pacemaker); uncompensated heart failure; marked&#xD;
             bradycardia (less than 50 beats/minute), Wolff-Parkinson-White syndrome, acute&#xD;
             myocardial infarction complicated by bradycardia, marked hypotension or left&#xD;
             ventricular failure&#xD;
&#xD;
          -  ECG second or third degree atrioventricular block&#xD;
&#xD;
          -  Any condition that in the investigator's opinion may adversely affect study&#xD;
             participation or may compromise the study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pieber, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dayan Colin, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Brunner, MSc</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>72841</phone_ext>
    <email>martina.brunner@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Brandner, MSc</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>72800</phone_ext>
    <email>karin.brandner@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Leitgeb, MSc</last_name>
      <phone>+43316385</phone>
      <phone_ext>80363</phone_ext>
      <email>silvia.leitgeb@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Pieber, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerlies Treiber, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Novak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harald Sourij, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Aberer, MD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Hochfellner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Harer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursule Van de Velde</last_name>
      <email>Ursule.VandeVelde@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Keymeulen, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aicha Hamouda</last_name>
      <email>aicha.hamouda@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Miriam Cnop, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rie Braspenning</last_name>
      <email>Rie.Braspenning@uza.be</email>
    </contact>
    <investigator>
      <last_name>Christophe De Block, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katholieke Universiteit</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut National de la Sante er de la Recherche Medicale</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Jones</last_name>
      <email>anna.jones@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Roberto Mallone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HKA Hannover</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BÃ¤rbel Aschemeier</last_name>
      <email>aschemeier@hka.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Danne, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤t Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefanie Lanzinger</last_name>
      <email>stefanie.lanzinger@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Reinhard Holl, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  vita salute San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabina Martinenghi</last_name>
      <email>martinenghi.sabina@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Bosi, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  degli Studi di Siena</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Formichi</last_name>
      <email>catefo@libero.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Dotta, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slaski Uniwersytet Medyczny w Katowicach</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GraÅ¼yna Deja</last_name>
      <email>gr.deja@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Przemyslawa Jarosz-Chobot, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lunds UniversitÃ¤t</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Lundgren</last_name>
      <email>markus.lundgren@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Markus Lundgren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Draxlbauer</last_name>
      <email>katharine.draxlbauer@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Feaz Babwah, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Schenede Coppin</last_name>
      <email>shenede.coppin@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Danijela Tatovic, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrokes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Kennet</last_name>
      <email>jk605@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Evans, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colin Dayan</last_name>
      <email>DayanCM@cardiff.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Colin Dayan, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bart's Hospital QMUL</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Pattrick</last_name>
      <email>m.pattrick@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Bobby Huda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olanike Okolo</last_name>
      <email>olanike.okolo@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Yuk-Fun Liu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tasso Gazis</last_name>
      <email>tasso.gazis@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tasso Gazis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OCDEM, John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katharine Owen, MD, Prof.</last_name>
      <email>katharine.owen@drl.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Katharine Owen, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Caunt</last_name>
      <email>sharon.count@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Sue Hudson</last_name>
      <email>susan.hudson3@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Heller, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Davies</last_name>
      <email>scott.davies@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steve Bain, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4;383(9911):69-82. doi: 10.1016/S0140-6736(13)60591-7. Epub 2013 Jul 26. Review.</citation>
    <PMID>23890997</PMID>
  </reference>
  <reference>
    <citation>DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018 Jun 16;391(10138):2449-2462. doi: 10.1016/S0140-6736(18)31320-5. Review.</citation>
    <PMID>29916386</PMID>
  </reference>
  <reference>
    <citation>Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014 Feb;63(2):739-48. doi: 10.2337/db13-0881. Epub 2013 Oct 2.</citation>
    <PMID>24089509</PMID>
  </reference>
  <reference>
    <citation>SÃ¸rensen JS, Johannesen J, Pociot F, Kristensen K, Thomsen J, Hertel NT, Kjaersgaard P, Brorsson C, Birkebaek NH; Danish Society for Diabetes in Childhood and Adolescence. Residual Î²-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 2013 Nov;36(11):3454-9. doi: 10.2337/dc13-0418. Epub 2013 Aug 29.</citation>
    <PMID>23990516</PMID>
  </reference>
  <reference>
    <citation>Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB, Thielen LA, Li P, Shalev A. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med. 2018 Aug;24(8):1108-1112. doi: 10.1038/s41591-018-0089-4. Epub 2018 Jul 9.</citation>
    <PMID>29988125</PMID>
  </reference>
  <reference>
    <citation>Yin T, Kuo SC, Chang YY, Chen YT, Wang KK. Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. J Clin Endocrinol Metab. 2017 Jul 1;102(7):2604-2610. doi: 10.1210/jc.2016-3778.</citation>
    <PMID>28368479</PMID>
  </reference>
  <reference>
    <citation>Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ; INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 1;98(7):890-4. Epub 2006 Aug 7.</citation>
    <PMID>16996868</PMID>
  </reference>
  <reference>
    <citation>Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes. 2008 Apr;57(4):938-44. doi: 10.2337/db07-0715. Epub 2008 Jan 2.</citation>
    <PMID>18171713</PMID>
  </reference>
  <reference>
    <citation>Xu G, Chen J, Jing G, Shalev A. Preventing Î²-cell loss and diabetes with calcium channel blockers. Diabetes. 2012 Apr;61(4):848-56. doi: 10.2337/db11-0955.</citation>
    <PMID>22442301</PMID>
  </reference>
  <reference>
    <citation>Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15.</citation>
    <PMID>23589542</PMID>
  </reference>
  <reference>
    <citation>Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. Review.</citation>
    <PMID>15855602</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INNODIA</keyword>
  <keyword>Typ-1 Diabetes</keyword>
  <keyword>Verapamil</keyword>
  <keyword>Beta cell</keyword>
  <keyword>C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

